Monte Rosa Therapeutics Inc (GLUE)

Jun 13, 2026

Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN

Jun 13, 2026

Jun 13, 2026

Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Alphabet Inc. - MarketBeat

Jun 13, 2026

Jun 12, 2026

Director at Monte Rosa (GLUE) awarded 25,800 stock options - Stock Titan

Jun 12, 2026

Jun 12, 2026

Monte Rosa Therapeutics (GLUE) director receives 25,800 stock options grant - Stock Titan

Jun 12, 2026

Jun 12, 2026

Monte Rosa Therapeutics (GLUE) director gets 25,800 options grant - Stock Titan

Jun 12, 2026

Jun 12, 2026

Monte Rosa Therapeutics (GLUE) grants director Jan Skvarka 25,800 options - Stock Titan

Jun 12, 2026

Jun 12, 2026

Monte Rosa Therapeutics (GLUE) director awarded 25,800 stock options - Stock Titan

Jun 12, 2026

Jun 12, 2026

Monte Rosa Therapeutics (GLUE) director granted 25,800 stock options - Stock Titan

Jun 12, 2026

Jun 12, 2026

Director at Monte Rosa (NASDAQ: GLUE) awarded 25,800 stock options - Stock Titan

Jun 12, 2026

Jun 11, 2026

Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential - Seeking Alpha

Jun 11, 2026

Jun 11, 2026

Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN

Jun 11, 2026

Jun 11, 2026

Monte Rosa Therapeutics (NASDAQ: GLUE) shareholders elect directors, ratify auditor - Stock Titan

Jun 11, 2026

Jun 05, 2026

GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com

Jun 05, 2026

Jun 04, 2026

GLUE Technical Analysis & Stock Price Forecast - Intellectia AI

Jun 04, 2026

Jun 04, 2026

GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill

Jun 04, 2026

Jun 03, 2026

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Insider Monkey

Jun 03, 2026

Jun 03, 2026

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate - Moomoo

Jun 03, 2026

Jun 02, 2026

10 Best Growth Stocks Under $20 to Buy - Insider Monkey

Jun 02, 2026

Jun 02, 2026

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 02, 2026

Jun 02, 2026

Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan

Jun 02, 2026

Jun 02, 2026

Monte Rosa Therapeutics (GLUE) amends Form 144; RSU award and sales noted - Stock Titan

Jun 02, 2026

Jun 01, 2026

Monte Rosa (GLUE) insider Markus Warmuth reports multiple sales on Form 144 - Stock Titan

Jun 01, 2026

Jun 01, 2026

Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan

Jun 01, 2026

May 29, 2026

[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan

May 29, 2026

May 28, 2026

Monte Rosa COO Jennifer Champoux sells $43,500 in stock By Investing.com - Investing.com Nigeria

May 28, 2026

May 28, 2026

Monte Rosa COO Jennifer Champoux sells $43,500 in stock - Investing.com India

May 28, 2026

May 28, 2026

Monte Rosa Therapeutics (NASDAQ: GLUE) COO exercises options and sells 2,175 shares - Stock Titan

May 28, 2026

May 27, 2026

GLUE (NASDAQ: GLUE) Form 144: proposed sale of 2,175 shares - Stock Titan

May 27, 2026

May 26, 2026

Monte Rosa (NASDAQ: GLUE) COO exercises options and sells 2,176 shares under plan - Stock Titan

May 26, 2026

May 23, 2026

Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com India

May 23, 2026

May 22, 2026

Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com UK

May 22, 2026

May 22, 2026

Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan

May 22, 2026

May 21, 2026

IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union

May 21, 2026

May 20, 2026

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

May 20, 2026

May 20, 2026

Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks - Stock Titan

May 20, 2026

May 16, 2026

Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

May 16, 2026

May 16, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

May 16, 2026

May 15, 2026

Monte Rosa Therapeutics (GLUE) — TCG/Chen Yu report 5.5% holding - Stock Titan

May 15, 2026

May 15, 2026

[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan

May 15, 2026

May 15, 2026

BVF Group (GLUE) entities report up to 5.09M shares, 6.3% total - Stock Titan

May 15, 2026

May 13, 2026

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail

May 13, 2026

May 12, 2026

EX-99.1 - SEC.gov

May 12, 2026

May 11, 2026

Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat

May 11, 2026

May 11, 2026

J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 - Moomoo

May 11, 2026

May 11, 2026

Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar - Traders Union

May 11, 2026

May 09, 2026

Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat

May 09, 2026

May 09, 2026

Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - Yahoo Finance

May 09, 2026